

Publication of the 2013 Registration Document

Paris, April 8, 2014 - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that its 2013 Registration Document, has been registered with the French Market Authorities (Autorité des Marchés Financiers) on April 7, 2014.

The Registration Document is available to the public free of charge upon request as per current legal regulations at BioAlliance Pharma's headquarters - 49 Boulevard du Général Martial Valin, 75015 Paris - and may be consulted at the <http://www.bioalliancepharma.com> website (under Investors).

The Annual Financial Report, the Report of the Chairman of the Board of Directors on corporate governance and on internal control and risk management procedures, as well as the Related Auditors' Report with information on the fees paid to the statutory auditors in 2013, are included in the 2013 Registration Document.

About BioAlliance Pharma

Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Orphan Oncology products

Livatag[®] (Doxorubicin Transdrug[™]) (primary liver cancer): Phase III on going

Validive[®] (Clonidine Lauriad[®]) (mucositis): Phase II on going

AMEP[®] (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2012 Reference Document filed with the AMF on April 18, 2013, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (.